Cancer Commons founder Marty Tenenbaum, PhD, will be speaking at a special MIT Club of Northern California event in Mountain View, CA, on September 23. From the event registration page:
“Every year 1.6 million Americans are diagnosed with cancer and nearly half of those cases are considered incurable. But many of those ‘incurable’ cases may be beatable by exploiting biological features unique to each individual’s cancer. I will talk about a convergence of recent developments in genomics, big data informatics, social networks, and personalized medicine that is transforming the landscape of cancer research and treatment. Instead of aiming our efforts toward curing ‘cancer’ in the abstract, and often failing, we are now on the threshold of being able to give each individual the knowledge, resources, and tools needed to successfully treat the one disease that matters most to them.”
The event is open to the public. Visit the registration page for details and pricing.
Earlier this year, Cancer Commons founder Marty Tenenbaum, PhD, spoke at the Bonnie J. Addario Lung Cancer Foundation’s (ALCF) monthly Lung Cancer Living Room event. Marty’s own cancer diagnosis and treatment journey inspired his current mission: to make sure critical information is shared and gets to the patients who need it. By collecting data from thousands of patient-donated lung cancer stories, Cancer Commons can begin to show patients and doctors patterns in treatment choices, side effects, quality of life, outcomes, and more.
The ALCF, one of our partner organizations, works directly with individual lung cancer patients to ensure they each receive the best possible care. The Lung Cancer Living Room is a monthly in-person and online support group event that informs patients about lung cancer.
Click here for more information, including how to attend in person (in San Carlos, CA) or online. Click here to read the description of Marty’s upcoming event.
On June 10, 2014, Cancer Commons held the inaugural event in its new Pathfinders Conversation Series (PCS). The Conversation brought together researchers, physicians, patients, the Cancer Commons team, and The Pathfinders (Cancer Commons’ donors) for an evening in Palo Alto, CA, to discuss some of the biggest challenges in cancer research today. Several guests who had personally dealt with cancer opened with their poignant stories, and the event progressed into a discussion of how existing data and information could be captured, analyzed, and shared more efficiently, for the benefit of all cancer patients.
“Information is the biggest deficit and really the lowest hanging fruit to changing the whole world of cancer,” said John Adler, MD, Professor Emeritus of Neurosurgery at Stanford University and Founder of Cureus. “As a community of physicians and patients, we need to take charge of our medical information and create something bigger than we can as individuals.”
Cancer Commons founder Marty Tenenbaum, PhD, recently visited Microsoft’s Richmond, CA, office to give a presentation entitled “How to Beat Cancer.”
Because of “a convergence of recent developments in genomics, big data informatics, social networks, and personalized medicine that is transforming the landscape of cancer research and treatment,” Marty says, “we are now on the threshold of being able to give each individual the knowledge, resources, and tools needed to successfully treat the one disease that matters most to them.”
The 6th annual PMWC conference in Silicon Valley runs Jan 27–28. It brings together leaders from multiple sectors—including business, government, healthcare-delivery, research and technology—to learn from each other and further the field of personalized medicine. Dr. Tenenbaum’s panel discussion is at 11 am on the main-stage. General registration is available through Jan 24.
Cancer Commons founder Marty Tenenbaum, PhD, will speak tomorrow at the Monte Jade Forum, an event organized by the Monte Jade Science and Technology Association (West Coast). The Forum is entitled Personalized Precision Medicine – What does it mean for the cancer patient? Dr. Tenenbaum will join oncologist Edmund Tai, MD, in a discussion of how personalized medicine, or “precision oncology,” can help cancer patients. Dr. Tenenbaum will discuss Cancer Commons as “an emerging patient-led movement that empowers each patient and their care team to get the best available knowledge for beating their cancer, and to update that knowledge in real time based on each patient’s outcome.”
The Forum takes place tomorrow, Nov 6, 2013, at 7:00pm at ITRI International in San Jose, CA. Registration is available online, and non-members can register for $20.
Cancer Commons founder Dr. Marty Tenenbaum will be speaking tomorrow at the monthly meeting of Silicom Ventures, a Silicon Valley-based investment forum. Dr. Tenenbaum will discuss his vision for a personalized approach to oncology, offering solutions that could help answer these questions:
-Which are the best drugs and trials for me?
-How can I get timely and affordable access to the latest investigational drugs?
-How can we slash the time and cost of drug development so that the economics work for therapies that target small subsets of patients?
-Can cancer research be funded, one patient at a time?
The meeting takes place tomorrow, Sep. 10, in Santa Clara, CA. Guest registration is available on the event page.
From June 26 to 27, lung cancer expert David M. Jackman, MD, will answer patient-submitted questions as a moderator on the social media cancer website CancerConnect. Dr. Jackman is a thoracic oncologist at Dana-Farber Cancer Institute in Boston. According to CancerConnect, “his research interests include evaluating how to predict responses to targeted therapy in non-small cell lung cancer (NSCLC).” Questions can be submitted here.
From June 26-27, lung cancer expert David M. Jackman, MD, will answer patient-submitted questions as a moderator on the social media cancer website CancerConnect. Dr. Jackman is a thoracic oncologist at Dana-Farber Cancer Institute. According to CancerConnect, “his research interests include evaluating how to predict responses to targeted therapy in non-small cell lung cancer (NSCLC).” Questions can be submitted here.